 1. Run-in Period 7-14 days: During the Run-in Period, subjects will maintain their current inhaled short-acting B2-agonist and inhaled corticosteroid therapies. All long-acting b-agonists LABA will be prohibited and replaced with a short-acting B2-agonist Ventolin-HFA and an inhaled corticosteroid, for a minimum of 7 days. Such LABA replacement therapy is not considered as violation of the asthma stability. The current orally inhaled corticosteroids may be maintained at the prescribed dosing regimen. All concomitant medications must be compliant or adjusted to the restrictions and washout time limits per Appendix II. Subjects will document their daily asthma symptom scores, treatment regimens, concomitant medications, PEF records, and adverse events if any. 